[1] FUCHS C S, DOI T, JANG R W J, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol, 2017, 35(Suppl15): 4003.
[2] Chinese Society of Clinical Oncology (CSCO). People's Medical Publishing House, 2019(1):41-43.
[3] KOTHARI N, ALMHANNAK. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol, 2015, 6(1):60-74. doi: 10.3978/j.issn.2078-6891.2014.098. PMID: 25642339; PMCID: PMC4294823.
[4] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373(1):23-34.
[5] Motzer RJ, Escudier B, Mcdermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med, 2015, 373(19): 1803-1813.
[6] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833.
[7] Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol, 2014, 20(7): 1657-1666.
[8] Niccolai E, Taddei A, Prisco D, et al. Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol, 2015, 21(19): 5778-5793.
[9] Bonotto M, Garattini SK, Basile D, et al. Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Rev Clin Pharmacol, 2017, 10(6): 609-619.
[10] Wagner T, Wirth J, Meyer J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell, 1994, 79 (6) :1111-1120.
[11] PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012, 12(4): 252-264.
[12] DAI C, WANG M, LU J, et al. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. Onco Targets Ther, 2017, 10: 3625-3634.
[13] Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010; 38: W214-20. https://doi.org/10.1093/nar/gkq537.
[14] Xie, C. et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Research 39, W316-W322 (2011).
[15] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. Nat Methods 7(4):248-249 (2010).
[16] Choi Y, Chan AP (2015) PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 31(16): 2745-2747.
[17] Reva, B.A., Antipin, Y.A. and Sander, C. Determinants of protein function revealed by combinatorial entropy optimization. (2007) Genome Biol, 8, R232.
[18] Wong WC, Kim D, Carter H, Diekhans M, Ryan M and Karchin R. (2011) CHASM and SNV Box: toolkit for detecting biologically important single nucleotide mutations in cancer Bioinformatics. 27(15):2147-2148.
[19] Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GLA, Edwards KJ, Day INM, Gaunt, TR. (2013). Predicting the Functional, Molecular and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models. Hum. Mutat. 34:57-65.
[20] M. Nielsen, C. Lundegaard, O. Lund, and C. Kesmir. The role of the proteasome in generating cytotoxic T cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 57(1-2):33-41, 2005.
[21] Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 10(8):424. 2007.
[22] Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016, 32(4):511-517. doi: 10.1093/bioinformatics/btv639. Epub 2015 Oct 29. PMID: 26515819; PMCID: PMC6402319.
[23] Reynisson B, Barra C, Kaabinejadian S, Hildebrand WH, Peters B, Nielsen M. Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. J Proteome Res. 2020, 19(6):2304-2315. doi: 10.1021/acs.jproteome.9b00874. Epub 2020 Apr 30. PMID: 32308001.
[24] Tang, Z. et al. (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 10.1093/nar/gkx247.
[25] Taiwen Li, Jingyu Fan, Binbin Wang, Nicole Traugh, Qianming Chen, Jun S. Liu, Bo Li, X. Shirley Liu. TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Research. 2017;77(21): e108-e110.
[26] Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9:166–80. https://doi.org/10.1593/neo.07112.
[27] Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19:649-658. https://doi.org/10.1016/j.neo.2017.05.002.
[28] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1. https://doi.org/10.1126/scisignal.2004088.
[29] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research 2003 Nov; 13(11):2498-2504.
[30] Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018; 46: D956-D63. https://doi.org/10.1093/nar/gkx1090.
[31] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
[32] Biagioni A, Skalamera I, Peri S, et al. Update on gastric cancer treatments and gene therapies. Cancer Metastasis Rev. 2019;38(3):537‐548. doi:10.1007/s10555-019-09803-7.
[33] PARDOLL D M. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[34] DAI C, WANG M, LU J, et al. Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis[J]. Onco Targets Ther, 2017, 10: 3625-3634.
[35] Choi YY, Kim H, Shin SJ, et al. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg, 270(2):309-316. doi: 10.1097/SLA.0000000000002803. PMID: 29727332.
[36] Gbolahan O, Hashemi-Sadraei N, O'Neil B. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. J Natl Compr Canc Netw. 2019, 17(6):644-648. doi: 10.6004/jnccn.2019.7304. PMID: 31200359.
[37] Fang H, Niu K, Mo D, Zhu Y, Tan Q, Wei D, Li Y, Chen Z, Yang S, Balajee AS, Zhao Y. RecQL4-Aurora B kinase axis is essential for cellular proliferation, cell cycle progression, and mitotic integrity. Oncogenesis. 2018; 7:68. https://doi.org/10.1038/s41389-018-0080-4.
[38] Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20:460-9. https://doi.org/10.1016/j.molmed.2014.06.005.
[39] Vaira V, Faversani A, Dohi T, et al. miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene. 2012;31(1):27-38. doi:10.1038/onc.2011.209.
[40] Wang X, Zhang H, Bai M, et al. Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer. Mol Ther. 2018;26(3):774-783. doi:10.1016/j.ymthe.2018.01.001.
[41] Moazeni-Roodi A, Ghavami S, Hashemi M. Association Between miR-423 rs6505162 Polymorphism and Susceptibility to Cancer. Arch Med Res. 2019;50(1):21-30. doi:10.1016/j.arcmed.2019.04.002.
[42] Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017;36(11):1461‐1473. doi:10.1038/onc.2016.304.
[43] Santos JC, Carrasco-Garcia E, Garcia-Puga M, et al. SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Cancer Res. 2016;76(22):6735‐6746. doi:10.1158/0008-5472.CAN-16-1120.